No significant differences were observed in the secondary end-points , including progression-free survival ( 4.6 [ 95 % CI : 3.4-5 .9 ] versus 4.1 [ 95 % CI : 3.3-4 .9 ] months ) and response rate ( 16.9 % [ 95 % CI : 8.8-28 .3 ] versus 15.4 % [ 95 % CI : 7.6-26 .5 ] ) .